Australian and Singapore based global leader in the manufacture of innovative regenerative implants Osteopore Limited (ASX: OSX) has signed a binding memorandum of understanding (MOU) with Singular Health Group Ltd (ASX: SHG).
The companies will work together to validate the results of an AI design-engine through a comparative study using a dataset provided by Osteopore.
Singular Health has been awarded a Kickstart 2 grant from Australia’s peak science agency, CSIRO, matching $50,000 of funding to conduct a project with CSIRO’s Data61 division to automatically generate patient specific cranial implants for craniotomies from CT scans.
The Kickstart 2 grant follows Singular Health’s highly successful Kickstart 1 project, which developed a spinal segmentation model with >95% accuracy and will see Singular’s technical team collaborate with Data61 to integrate the model into the 3Dicom Virtual Surgical Planning software.
Osteopore’s collaboration with Singular Health will commence after the successful completion of the CSIRO Data61 project. The scope of the binding MOU is limited to the provision of a dataset of 40 craniotomy scans and existing cranial implants for validation of the AI-model with requisite ethics approvals for research and commercial usage; a $10,000 contribution towards the collaboration in cash and in-kind; and the execution of formal collaboration documents within 60 days of executing the MOU, or as agreed by the parties.
The purpose of this six to 12 month collaboration is to conduct a comparative study to test and validate the accuracy and efficiency provided by the automated generation of patient specific cranial implant designs.
Osteopore’s CEO, Khoon Seng Goh, said the significance of this cooperative undertaking lies in the potentially significant design and process improvement opportunities afforded by Singular Health’s AI technology and Osteopore looks forward to future collaborations and commercialisation prospects.
As a leader in regenerative medicine, Osteopore collaborates with a range of technologies that improve the efficacy of our regenerative implants,” Mr Khoon Seng Goh said.
“This win-win formula brings future technologies to commercialisation faster so that surgeons have new solutions for their treatment strategy, and patients can be treated early to make the most of their body’s healing capacity.”
Thomas Hanly, Singular Health’s CEO, said the project marks an exciting step for Singular Health as it highlights our expertise in Artificial Intelligence in the design of patient specific implants.
“Too often, advances in medical technology are made without the input of peers to focus on commercial priorities. Working with Osteopore ensures our work and results will be objectively compared with existing techniques and paves the way for future collaborations and commercialisation opportunities.”
